Naproxcinod

Drug Profile

Naproxcinod

Alternative Names: AZD 3582; HCT 3012; Naproxen nitroxybutylester; Nitronaproxen; NO-naproxen

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator NicOx
  • Class Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Osteoarthritis
  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 10 Nov 2015 Naproxcinod licensed to Fera Pharmaceuticals in USA
  • 28 Aug 2015 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (PO)
  • 19 Mar 2015 Naproxcinod receives Orphan Drug status for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top